{
    "symbol": "NVCR",
    "quarter": 4,
    "year": 2022,
    "date": "2023-02-23 12:04:05",
    "content": " In our commercial business, we generated $538 million in net revenue, received approval for and launched Optune in Canada, and finalized contract terms to establish national reimbursement in France, pending final publication; we successfully rolled out our next generation arrays in Austria, which are thinner, lighter, and may deliver more energy to patients; and we made significant progress in our clinical programs, announcing the pivotal LUNAR study and non-small cell lung cancer met its primary overall survival endpoint; completing the pivotal INNOVATE-3 interim analysis with final INNOVATE-3 data anticipated later this year; and announcing positive data in our pilot gastric cancer study and in Dr. David Tran's 2-THE-TOP pilot study, which explored treating GBM patients with TTFields plus temozolomide and the immune checkpoint inhibitor, pembrolizumab."
}